1. Academic Validation
  2. Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis

Mutations in PDGFRB cause autosomal-dominant infantile myofibromatosis

  • Am J Hum Genet. 2013 Jun 6;92(6):1001-7. doi: 10.1016/j.ajhg.2013.04.024.
John A Martignetti 1 Lifeng Tian Dong Li Maria Celeste M Ramirez Olga Camacho-Vanegas Sandra Catalina Camacho Yiran Guo Dina J Zand Audrey M Bernstein Sandra K Masur Cecilia E Kim Frederick G Otieno Cuiping Hou Nada Abdel-Magid Ben Tweddale Denise Metry Jean-Christophe Fournet Eniko Papp Elizabeth W McPherson Carrie Zabel Guy Vaksmann Cyril Morisot Brendan Keating Patrick M Sleiman Jeffrey A Cleveland David B Everman Elaine Zackai Hakon Hakonarson
Affiliations

Affiliation

  • 1 Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA; Department of Pediatrics, Mount Sinai School of Medicine, New York, NY 10029, USA; Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA. Electronic address: [email protected].
Abstract

Infantile myofibromatosis (IM) is a disorder of mesenchymal proliferation characterized by the development of nonmetastasizing tumors in the skin, muscle, bone, and viscera. Occurrence within families across multiple generations is suggestive of an autosomal-dominant (AD) inheritance pattern, but autosomal-recessive (AR) modes of inheritance have also been proposed. We performed whole-exome sequencing (WES) in members of nine unrelated families clinically diagnosed with AD IM to identify the genetic origin of the disorder. In eight of the families, we identified one of two disease-causing mutations, c.1978C>A (p.Pro660Thr) and c.1681C>T (p.Arg561Cys), in PDGFRB. Intriguingly, one family did not have either of these PDGFRB mutations but all affected individuals had a c.4556T>C (p.Leu1519Pro) mutation in NOTCH3. Our studies suggest that mutations in PDGFRB are a cause of IM and highlight NOTCH3 as a candidate gene. Further studies of the crosstalk between PDGFRB and Notch pathways may offer new opportunities to identify mutations in other genes that result in IM and is a necessary first step toward understanding the mechanisms of both tumor growth and regression and its targeted treatment.

Figures